Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | AVPR1A | P37288 | 13/20 | 0.46 |
| ▸ | AVPR2 | P30518 | 11/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307691 | 0.86 | ALDH1A1 (0.48) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL3456081 | 0.84 | AVPR1A (0.54) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL1307830 | 0.83 | ALDH1A1 (0.47) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL1307851 | 0.82 | ALDH1A1 (0.54) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL1307391 | 0.81 | LMNA (0.48) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL1306946 | 0.81 | LMNA (0.48) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL1308165 | 0.80 | ALDH1A1 (0.56) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL1308903 | 0.80 | ALDH1A1 (0.52) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL3456851 | 0.80 | ALDH1A1 (0.55) | LMNAALDH1A1MEN1HTTKMT2A | |
| SCHEMBL1306910 | 0.79 | MEN1 (0.45) | LMNAALDH1A1MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | claimed |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, CYP11B1, HSD11B2 | LMNA 3649/4885ALDH1A1 187/4885MEN1 1971/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | LMNA 3468/4885ALDH1A1 206/4885MEN1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.